Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX (TAST)

This study has been completed.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: June 4, 2008
Last updated: August 25, 2014
Last verified: August 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2004
  Primary Completion Date: March 2004 (Final data collection date for primary outcome measure)